The notices it replaced
- Reissues: PAR-15-095 Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (UH2/UH3)
Replaced by PAR-20-313.
Who won it before
21 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,948,929 in first-year total cost, median $214,027.
Most frequent study sections
- Special Emphasis Panel[ZCA1 TCRB-T (O1)]5
- Special Emphasis Panel[ZCA1 RPRB-8 (O2)]2
- Special Emphasis Panel[ZCA1 RPRB-B (O1)]2
- Special Emphasis Panel[ZCA1 RTRB-F (M1)]2
- Special Emphasis Panel[ZCA1 TCRB-Q (J3)]2
Most frequent institutions
- OHIO STATE UNIVERSITY3
- MAYO CLINIC ARIZONA2
- BROAD INSTITUTE, INC.1
- CASE WESTERN RESERVE UNIVERSITY1
- COLUMBIA UNIVERSITY HEALTH SCIENCES1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Validation of a saliva test using methylated microRNAs for head and neck cancer recurrence1UH2CA262045-01 | LU, SHI-LONG | UNIVERSITY OF COLORADO DENVER, CO | $273,315 | ZCA1 |
| 2021 | Liquid Biopsy for Rapid Detection and Real Time Monitoring of FGFR-altered Cancers1UH2CA262220-01 | ROYCHOWDHURY, SAMEEK | OHIO STATE UNIVERSITY, OH | $242,424 | ZCA1 |
| 2021 | Validation of predictive liquid biomarkers for patients with metastatic prostate cancer1UH2CA260389-01 | ARMSTRONG, ANDREW JHALABI, SUSANLANG, JOSHUA MICHAELRATHKOPF, DANA | UNIVERSITY OF WISCONSIN-MADISON, WI | $191,368 | ZCA1 |
| 2020 | HRD-IA signatures in pancreatic ductal adenocarcinoma1UH2CA238926-01A1 | BARRETT, MICHAEL T | MAYO CLINIC ARIZONA, AZ | $260,968 | ZCA1 |
| 2020 | Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers1UH2CA239105-01A1 | ADALSTEINSSON, VIKTORLENNON, NIALL JOHNSTOVER, DANIEL G. | BROAD INSTITUTE, INC., MA | $214,899 | ZCA1 |
| 2020 | Plasma biomarkers for lung cancer diagnosis1UH2CA251139-01 | JIANG, FENG | UNIVERSITY OF MARYLAND BALTIMORE, MD | $184,821 | ZCA1 |
| 2020 | Treatment monitoring in early and locally advanced breast cancer using circulating tumor DNA analysis1UH2CA234306-01A1 | MURTAZA, MUHAMMED | TRANSLATIONAL GENOMICS RESEARCH INST, AZ | $102,573 | ZCA1 |
| 2019 | CLINCIAL VALIDATION OF APC AND TP53 AS BIOMARKERS FOR CETUXIMAB RESPONSE1UH2CA227955-01A1 | YEATMAN, TIMOTHY J | UNIVERSITY OF UTAH, UT | $339,695 | ZCA1 |
| 2019 | Assay Validation of a Circulating miRNA Test for Diagnosis and Monitoring of Malignant Germ Cell Tumors1UH2CA240688-01 | FRAZIER, ANNE LINDSAY | DANA-FARBER CANCER INST, MA | $215,895 | ZCA1 |
| 2019 | A prognostic mRNA immune signature for resected stage II-III melanoma1UH2CA218149-01A1 | KROLEWSKI, JOHN J.SAENGER, YVONNE MARGARET | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $197,614 | ZCA1 |
| 2018 | Colorectal Cancer Molecular Subtype Assay Development and Validation1UH2CA207101-01A1 · under PAR-15-095 | KOPETZ, SCOTTLUTHRA, RAJYALAKSHMIMARU, DIPEN M.MORRIS, JEFFREY S | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $214,027 | ZCA1 |
| 2018 | Clinical development of a blood based assay that detects the BRAF V600E mutation in melanoma and thyroid cancer patients1UH2CA207355-01A1 · under PAR-15-095 | SULLIVAN, RYAN J | MASSACHUSETTS GENERAL HOSPITAL, MA | $140,135 | ZCA1 |
| 2017 | Detection of microsatellite instability biomarkers for therapeutic clinical trial eligibility1UH2CA216432-01 · under PAR-15-095 | ROYCHOWDHURY, SAMEEK | OHIO STATE UNIVERSITY, OH | $354,168 | ZCA1 |
| 2017 | Molecular diagnostic and prognostic signatures for PTCL1UH2CA206127-01A1 · under PAR-15-095 | CHAN, WING C.IQBAL, JAVEED | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $205,470 | ZCA1 |
| 2017 | Development of Mantle Cell Lymphoma Proliferation Signature Assay1UH2CA217847-01 · under PAR-15-095 | RIMSZA, LISA | MAYO CLINIC ARIZONA, AZ | $198,578 | ZCA1 |
| 2017 | Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients1UH2CA206126-01A1 · under PAR-15-095 | CHIA, DAVID S.DAS, KINGSHUKSOO HOO, GUYWEI, FANGWONG, DAVID T | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $184,223 | ZCA1 |
| 2017 | Optimizing an assay for high risk HPV DNA in body fluids1UH2CA211396-01 · under PAR-15-095 | CALIFANO, JOSEPH A | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $128,218 | ZCA1 |
| 2016 | Validation of EGFR Protein Complexes as Molecular Diagnostics1UH2CA202970-01 · under PAR-15-095 | HAURA, ERIC B. | H. LEE MOFFITT CANCER CTR & RES INST, FL | $390,763 | ZCA1 |
| 2016 | Assay Validation of Targeted RNA sequencing to Detect Kinase Gene Fusions1UH2CA202971-01 · under PAR-15-095 | ROYCHOWDHURY, SAMEEK | OHIO STATE UNIVERSITY, OH | $351,505 | ZCA1 |
| 2016 | Validation of Methylated Vimentin as a Diagnostic Test for Barrett's Esophagus1UH2CA205105-01 · under PAR-15-095 | WILLIS, JOSEPH EDWARD | CASE WESTERN RESERVE UNIVERSITY, OH | $346,395 | ZCA1 |
| 2016 | Validation of circulating tumor DNA assays for detection of metastatic melanoma1UH2CA206124-01 · under PAR-15-095 | POLSKY, DAVID | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $211,875 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.